The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

KEYNOTE-991 trial evaluating Keytruda + Xtandi + androgen deprivation therapy in hormone-sensitive prostate cancer is stopped for futility

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Merck will stop the phase III KEYNOTE-991 trial investigating Keytruda (pembrlizumab), Merck’s anti-PD-1 therapy, in combination with Xtandi (enzalutamide) and androgen deprivation therapy for the treatment of patients with metastatic, hormone-sensitive prostate cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

FDA approves Keytruda and Keytruda Qlex + Padcev as perioperative treatment cisplatin-ineligible bladder cancer

FDA approved Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. These approvals represent the first PD-1 inhibitor plus ADC regimens for this patient population.
Clinical Roundup

GammaTile delivers superior tumor control vs. standard-of-care for newly diagnosed operable brain metastases

GammaTile showed superiority in the primary endpoint of the study. Patients who received GammaTile lived longer without tumor regrowth, reducing the risk of either tumor recurrence or death by 50% reduction compared to standard of care, according to interim results from the ROADS clinical trial, which evaluated GammaTile versus standard of care in patients with operable, newly diagnosed brain metastases.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account